亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。
返回搜索结果

Biomarkers for Alzheimer's Disease Diagnosis

详细技术说明
CornellResearchers have identified a set of Alzheimer's disease-specific proteinbiomarkers that can be used in the analysis of cerebrospinal fluid (CSF) todiagnose Alzheimer's disease (AD) patients.
*Abstract

Alzheimer’s disease is the leadingcause of dementia amongst the elderly, yet a diagnosis cannot be made until theonset of the disease.  According to the Alzheimer’sAssociation, in 2016 an estimated 5.2 million of American people age 65 andolder have Alzheimer's disease and the number are projected to reach 13.8million by 2050.  Early detection of ADis essential to a holistic management of the disease (medication to delay theprogress, health care cost, etc.). 

 

The technology developed by Cornellresearchers allows for an early diagnostic of AD and comprises:

  1. A panelof specific multiplexed biomarkers in CSF that could be used to quantitativelydifferentiate between samples from AD patients and from non-AD patients
  2.  An associated database with information onprotein expression levels that are and are not associated with AD.

 

Thistechnology enables early detection of AD, thus allows for adequate treatment strategies. It has been tested together with aclinical trial of AD therapeutics.  Apanel of 23 spots was identified that could be used to differentiate AD andnon-AD gels with a sensitivity of 94%, a specificity of 94%, and a predictedclassification error rate of only 5.9%. The figure below. shows the abilityof the biomarkers panel to isolate AD from non-AD patients amongst 68 cerebrospinal fluid samples).

 

 

PotentialApplications

Earlydiagnostic test for Alzheimer's disease.

 

Advantages

  • Anearly diagnostic test would eliminate false positives, allowing doctors toexplore disease possibilities other than AD.
  • Thisdiagnostic method is comprehensive, compared to existing methods that mustemploy several different tests to detect AD.
  • Thediagnostics can be done using ELISA and other techniques.

  
*Licensing
Phillip Owh607-254-4508po62@cornell.edu
其他
  • U.S. Patent 9,335,331
  • Choi Y,Choe LH, Lee KH (2010). Recent cerebrospinal fluid biomarker studies ofAlzheimer's disease. Expert Review ofProteomics 7: 919-926. PMID: 21142892. DOI: 10.1586/epr.10.75
  • FinehoutE.J., et al. (2007). Cerebrospinal Fluid Proteomic Biomarkers for Alzheimer'sDisease. Annals of Neurology 61,120-129. DOI: 10.1002/ana.21038
  • Choe L,et al. (2007). 8-Plex quantitation of changes in cerebrospinal fluid proteinexpression in subjects undergoing intravenous immunoglobulin treatment forAlzheimer’s disease. Proteomics7(20):3651-3660. DOI: 10.1002/pmic.200700316.
国家/地区
美国

欲了解更多信息，请点击 这里
移动设备